Clinical trials: Diabetes Type 2
Diabetes Mellitus, Type 2
RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes
This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week run-in period will be followed by a median of 6 years of treatment with study medication in addition to continuation of background…
- Trial name
- RECORD (NCT00379769)
- Testing
- Rosiglitazone, Sulfonylurea, Metformin
- Where
- 446 sites in Australia, Belgium and 23 more
- Volunteers
- 4,447 people
- Sponsor
- GlaxoSmithKline
Diabetes Mellitus, Type 2
Comparative Effectiveness of Diabetes Shared Medical Appointment Models
In this study, the investigators will compare the effectiveness of patient-driven diabetes Shared Medical Appointments (SMAs) to standardized diabetes SMAs.
- Trial name
- NCT03590041
- Testing
- Standardized SMA, Patient-driven SMA
- Where
- United States
- Volunteers
- 1,085 people
- Sponsor
- University of Colorado, Denver
Peer Support and Chronic Disease, Obesity
Peer Support Dyads in Churches
The purpose of this study is to explore how working with a partner can influence participation in a church wellness program. There are many different types of church wellness programs.
- Conditions
- Peer Support and Chronic Disease, Obesity, Type II Diabetes, Cardiovascular Disease
- Trial name
- NCT03463941
- Testing
- Peer Support Dyad Intervention
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Duke University
Type 1 Diabetes
The Summer Camp Study 2: Blood Glucose Control With a Bi-Hormonal Endocrine Pancreas
This study will test the hypothesis that a wearable automated bionic pancreas system that automatically delivers both insulin and glucagon can improve glycemic control vs.
- Trial name
- NCT02105324
- Testing
- Bionic Pancreas, Usual Care
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Massachusetts General Hospital
Diabetes type1, Children, Only
Evaluation of the MiniMed 780 System in Paediatric Subjects
The purpose of this study is to demonstrate the safety and performance of the MiniMed™ 780G system in pediatric subjects (2-6 years old) with type 1 diabetes in a home setting.
- Trial name
- LENNY (NCT05574062)
- Testing
- MiniMed 780G Auto Mode with G4S sensor, MiniMed 780G Manual Mode with G4S sensor, MiniMed 780G Auto Mode with DS5 sensor
- Where
- 12 sites in Finland, Italy and 2 more
- Volunteers
- 101 people
- Sponsor
- Medtronic MiniMed, Inc.
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-3)
The purpose of this study is to determine if LY2189265 is safe and effective in reducing glycosylated hemoglobin (HbA1c) as compared to metformin in participants with Type 2 Diabetes.
- Trial name
- NCT01126580
- Testing
- Metformin, LY2189265
- Where
- 91 sites in United States, Argentina and 17 more
- Volunteers
- 807 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Diabetic Kidney Disease
DiEtary Sodium Intake Effects on Ertugliflozin-induced Changes in GFR, reNal Oxygenation and Systemic Hemodynamics: the DESIGN Study
SGLT2 inhibitors such as ertugliflozin improve blood pressure and kidney outcomes in people living with diabetes through incompletely understood mechanisms, however, not all patients treated with SGLT2 inhibition have improved…
- Conditions
- Diabetes Mellitus, Diabetic Kidney Disease, Hypertension
- Trial name
- DESIGN (NCT05727579)
- Testing
- Salt-Diet and/or Ertugliflozin, Ertugliflozin 15 mg
- Where
- Netherlands
- Volunteers
- 41 people
- Sponsor
- Amsterdam UMC, location VUmc
Diabetes Mellitus, Type 2
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Metformin
The purpose of this study is to evaluate the benefits and risks of lixisenatide (AVE0010), in comparison to placebo, as an add-on treatment to metformin, over a period of 24 weeks of treatment, followed by an extension.
- Trial name
- GETGOAL-F1 (NCT00763451)
- Testing
- Lixisenatide (AVE0010), Pen auto-injector, Metformin
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 484 people
- Sponsor
- Sanofi
Diabetes Type 2, Diabetes Mellitus
A Study of Tirzepatide (LY3298176) in Chinese Participants With Type 2 Diabetes
The main purpose of this study is to compare the effect of the addition of tirzepatide or placebo to titrated basal insulin on glycemic control in Chinese participants with type 2 diabetes.
- Conditions
- Diabetes Type 2, Diabetes Mellitus, Glucose Metabolism Disorders, Metabolic Disease
- Trial name
- SURPASS-CN-INS (NCT05691712)
- Testing
- Tirzepatide
- Where
- 25 sites in China
- Volunteers
- 257 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Study Assessing Saxagliptin Treatment In Type 2 Diabetic Subjects Who Are Not Controlled With Metformin Alone
The purpose of this clinical research study is to learn whether Saxagliptin added to Metformin therapy is more effective than Metformin alone as a treatment for type 2 diabetic subjects who are not sufficiently controlled with…
- Trial name
- NCT00121667
- Testing
- Saxagliptin + Metformin, Pioglitazone
- Where
- 152 sites in United States, Argentina and 7 more
- Volunteers
- 1,462 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
Continuous Glucose Monitoring and Behavioral Change Intervention for People With Type 2 Diabetes and Diabetes Distress
The purpose of this study is to use a Personalized Trial (N-of-1) design to test the effect of an intervention that pairs continuous glucose monitoring (CGM) with text message-delivered behavior change interventions for physical…
- Trial name
- NCT05941000
- Testing
- Self-Monitoring of Behavior for Physical Activity, Action Planning for Physical Activity, Self-Monitoring of Behavior for Mood
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Northwell Health
Type 2 Diabetes Mellitus
Efficacy and Safety of Sotagliflozin Versus Placebo in Patients With Type 2 Diabetes Mellitus Not Currently Treated With Antidiabetic Therapy
Primary Objective: To demonstrate the superiority of Sotagliflozin 400 milligrams (mg) versus placebo on hemoglobin A1c (HbA1c) reduction in participants with type 2 diabetes (T2D) who have inadequate glycemic control on diet and…
- Trial name
- NCT02926937
- Testing
- Sotagliflozin (SAR439954)
- Where
- 70 sites in United States, Canada and 1 more
- Volunteers
- 399 people
- Sponsor
- Lexicon Pharmaceuticals
Type 2 Diabetes Mellitus
Sitagliptin Cardiovascular Outcomes Study (MK-0431-082)
This is a clinical trial designed to assess the cardiovascular outcome of long-term treatment with sitagliptin used as part of usual care compared to usual care without sitagliptin in participants with type 2 diabetes mellitus…
- Trial name
- TECOS (NCT00790205)
- Testing
- Sitagliptin
- Volunteers
- 14,671 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"
The purpose of this survey is to evaluate the long-term safety and efficacy of the alogliptin and metformin hydrochloride combination tablet in type 2 diabetes mellitus patients with renal impairment (mild), hepatic impairment…
- Trial name
- NCT03555565
- Testing
- Alogliptin and Metformin hydrochloride
- Where
- Japan
- Volunteers
- 1,026 people
- Sponsor
- Takeda
Diabetes Mellitus, Type 2
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine.
- Trial name
- NCT02197520
- Testing
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetes, Diabetes Mellitus, Type 2
Comparing Efficacy and Safety of Insulin Degludec/Insulin Aspart Twice Daily and Biphasic Insulin Aspart Twice Daily in Subjects With Type 2 Diabetes Mellitus Before, During and After Ramadan
This trial is conducted in Africa and Asia. The aim of this trial is to compare efficacy and safety of insulin degludec/insulin aspart twice daily and biphasic insulin aspart twice daily in subjects with type 2 diabetes mellitus…
- Trial name
- NCT02648217
- Testing
- insulin degludec/insulin aspart, biphasic insulin aspart
- Where
- 32 sites in Algeria, India and 4 more
- Volunteers
- 263 people
- Sponsor
- Novo Nordisk A/S
Diabetes
Technology-assisted Case Management in Adults With Type 2 Diabetes
The purpose of this study is to help low income patients achieve and maintain better self-management skills and improve blood sugar levels, using a 2-in-1 blood glucose and blood pressure monitoring system and nurse case…
- Trial name
- TACM-DM (NCT01373489)
- Testing
- Technology-Assisted Case Management
- Where
- United States
- Volunteers
- 113 people
- Sponsor
- State University of New York at Buffalo
Diabetes, Diabetes Mellitus, Type 2
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
This trial is conducted in Europe, Africa and the United States of America (USA). The aim of this trial is to compare the safety and efficacy of two different insulin treatments, the "basic" and the "advanced" treatment in type 2…
- Trial name
- NCT00537303
- Testing
- insulin detemir, insulin aspart
- Where
- 69 sites in United States, Denmark and 10 more
- Volunteers
- 296 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus
This study is designed to assess the safety, tolerability and pharmacodynamics of 6 weeks of oral doses of PF-05175157 provided as monotherapy in subjects with type 2 diabetes mellitus.
- Trial name
- NCT01792635
- Testing
- PF-05175157
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Pfizer
Type 2 Diabetes
Roflumilast Plus Alogliptin Proof-of-Mechanism Study in Type2 Diabetes
The purpose of this study is to assess the effect of roflumilast plus alogliptin on glucagon-like peptide-1 (GLP-1) and glucose levels in patients with type 2 diabetes.
- Trial name
- NCT01664624
- Testing
- Roflumilast, Alogliptin, Exenatide
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.